Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 4Active not recruiting 3Terminated 2

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 1Head & Neck 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Papillomavirus Infections 1Oropharyngeal Neoplasms 1Lymphoma, Follicular 1Lymphoma 1

Interventions

Cyclophosphamide 241Radiotherapy 217Gemcitabine 187Cisplatin 185Carboplatin 182Docetaxel 166Bevacizumab 166Paclitaxel 144Capecitabine 142Rituximab 141pembrolizumab 140Nivolumab 126Oxaliplatin 124Dexamethasone 122Fluorouracil 113fludarabine 104Radiosurgery 101Doxorubicin 99fludarabine phosphate 97Irinotecan 96Etoposide 95Lenalidomide 93Cytarabine 92Magnetic Resonance Spectroscopy 90Radiation 89Filgrastim 89Leucovorin 88Bortezomib 86Cetuximab 80Pemetrexed 79

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × OTHER × utomilumab × Clear all
NCT03636503 2025-02-06

Rituximab + Immunotherapy in Follicular Lymphoma

Dana-Farber Cancer Institute

Phase 1 Terminated
24 enrolled 25 charts
Lymphoid

Lymphoma, Lymphoma, Follicular

NCT03258008 2022-12-16

Utomilumab and ISA101b Vaccination in Patients With HPV-16-Positive Incurable Oropharyngeal Cancer

M.D. Anderson Cancer Center

Phase 2 Terminated
3 enrolled 7 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Oropharyngeal Neoplasms, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡